Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Meiji Bags Japan Approval for 2-Dose COVID Vaccine Vial
Meiji Seika Pharma said on August 29 that it has gained Japanese regulatory approval for a two-dose vial version of its next-generation mRNA COVID-19 vaccine Kostaive. The approval was granted on August 28.The vaccine has been shown to induce neutralizing…
To read the full story
Related Article
- Meiji Rolls Out 2-Dose Vial of COVID-19 Vaccine Kostaive
September 29, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- 2-Dose Vial of COVID Vaccine Filed in Japan: Meiji
March 3, 2025
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…